NCT06730412View on ClinicalTrials.gov

CtDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Trial Locations (1)

02114

Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors

collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Massachusetts General Hospital

OTHER

lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT06730412 - CtDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca) | Biotech Hunter | Biotech Hunter